company background image
INM logo

InMed Pharmaceuticals NasdaqCM:INM Stock Report

Last Price

US$0.35

Market Cap

US$2.1m

7D

-4.6%

1Y

-70.1%

Updated

27 Mar, 2024

Data

Company Financials +

InMed Pharmaceuticals Inc.

NasdaqCM:INM Stock Report

Market Cap: US$2.1m

INM Stock Overview

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products.

INM fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

InMed Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for InMed Pharmaceuticals
Historical stock prices
Current Share PriceUS$0.35
52 Week HighUS$2.08
52 Week LowUS$0.29
Beta0.46
1 Month Change-19.31%
3 Month Change-10.61%
1 Year Change-70.10%
3 Year Change-99.58%
5 Year Change-99.90%
Change since IPO-99.84%

Recent News & Updates

Recent updates

InMed Pharmaceuticals GAAP EPS of -$33.17, revenue of $1.09M

Sep 26

InMed Pharma announces $6M private placement

Sep 09

InMed Pharma says phase 2 trial for skin disorder cannabinol cream can now include teens

Jul 25

InMed Pharmaceuticals gets non-compliance notice on Nasdaq minimum bid price requirement

Jul 13

InMed To Acquire Rare Cannabinoid Manufacturer BayMedica

Jul 02

InMed's INM-755 CBN cream did not introduce any delay in normal wound healing

Jan 08

Shareholder Returns

INMUS PharmaceuticalsUS Market
7D-4.6%1.2%0.4%
1Y-70.1%25.8%28.8%

Return vs Industry: INM underperformed the US Pharmaceuticals industry which returned 23.9% over the past year.

Return vs Market: INM underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is INM's price volatile compared to industry and market?
INM volatility
INM Average Weekly Movement10.2%
Pharmaceuticals Industry Average Movement9.7%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: INM's share price has been volatile over the past 3 months.

Volatility Over Time: INM's weekly volatility has decreased from 15% to 10% over the past year.

About the Company

FoundedEmployeesCEOWebsite
198113Eric Adamshttps://www.inmedpharma.com

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products.

InMed Pharmaceuticals Inc. Fundamentals Summary

How do InMed Pharmaceuticals's earnings and revenue compare to its market cap?
INM fundamental statistics
Market capUS$2.10m
Earnings (TTM)-US$6.35m
Revenue (TTM)US$5.49m

0.4x

P/S Ratio

-0.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
INM income statement (TTM)
RevenueUS$5.49m
Cost of RevenueUS$3.38m
Gross ProfitUS$2.11m
Other ExpensesUS$8.46m
Earnings-US$6.35m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.05
Gross Margin38.42%
Net Profit Margin-115.75%
Debt/Equity Ratio0%

How did INM perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.